AMICUS THERAPEUTICS, INC. — Director's Dealing 2020

Jan 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2019-12-31

Reporting Person: Campbell Bradley L (Director, Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-31	Common Stock	F	15556	$9.74	Disposed	253987	Direct
2020-01-02	Common Stock	A	119780	—	Acquired	373767	Direct
2020-01-02	Common Stock	S	14627	$9.5611	Disposed	359140	Direct
2020-01-02	Common Stock	M	7500	$5.96	Acquired	366640	Direct
2020-01-02	Common Stock	S	7500	$9.6052	Disposed	359140	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-02	Stock Options (right to buy)	$9.55	A	188257	Acquired	2030-01-02	Common Stock (188257)	Direct
2020-01-02	Stock Options (right to buy)	$5.96	M	7500	Disposed	2021-01-19	Common Stock (7500)	Direct

Footnotes

F1: Granted in the form of Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Amicus common stock.

F2: The Restricted Stock Units will vest in four equal annual installments beginning on January 2, 2021.

F3: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.51 to $9.61. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.50 to $9.72. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on the first anniversary of the grant date. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments beginning on the first month thereafter.

F7: All of the options were fully vested and exercisable as of January 2, 2020.